EDGC Issues 224.8 Million New Shares in Debt-to-Equity Swap under Rehabilitation Plan… Massive Dilution Poses Severe Risk to Existing Shareholders
EDGC decided to issue 224,797,110 common shares (par value 100 won) via third-party allotment under its approved rehabilitation plan
Issue price is 100 won, a 76% discount to current price of 415 won, leading to severe dilution of existing shareholders' equity value
New shares represent a 162% increase over pre-issuance outstanding shares (138,493,951), inevitably reducing per-share value
The capital increase is a debt-to-equity swap to repay debts, replacing board and shareholder resolutions with court approval
No new cash inflow; existing rehabilitation claims are converted to shares to improve financial structure
Listing date of new shares postponed from June 1 to June 2, 2026 due to procedural delays
Allottees include major creditors like Blue Dot Midas Global Private Equity and Bitna Electronics
Fractions of shares less than one will be cancelled without compensation
[AI Comprehensive Analysis]This capital increase is an unavoidable step in the rehabilitation process for the company's survival, but for existing shareholders, it is a severe adverse event: massive new shares issued at a 76% discount, causing a sharp drop in equity value. Short-term downside pressure is significant, and investors should monitor further dilution risks and potential changes in control.
KOSDAQ Filing Information
Filing: [Correction of Description] Report on Major Events (Decision on Paid-in Capital Increase)
Company: Eone Diagnomics Genome Center (245620)
Submission: Eone Diagnomics Genome Center Co., Ltd.